Text Size

Vancomycin vs. Vancomycin Plus Gentamycin in Treatment of MRSA Infection

This study has been completed.
Sponsor:
Collaborator:
Baylor College of Medicine
Information provided by:
VA Medical Center, Houston
ClinicalTrials.gov Identifier:
NCT00304811
First received: March 16, 2006
Last updated: September 25, 2009
Last verified: September 2009
History of Changes
  Purpose

The purpose of this study is to compare the outcome of treatment for bacteremic MRSA infection with vancomycin alone, vancomycin plus gentamicin, vancomycin plus rifampin, and vancomycin plus gentamicin and rifampin.


Condition Intervention Phase
Staphylococcus Aureus
 Drug: Vancomycin
Drug: Vancomycin plus Gentamicin
Drug: Vancomycin plus Rifampin
Drug: Vancomycin plus Gentamicin plus Rifampin
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Official Title: Vancomycin Versus Vancomycin Plus Gentamycin For Treating Bacteremic Infection Due to Methicillin-Resistant Staphylococcus Aureus (MRSA)

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by VA Medical Center, Houston:

Primary Outcome Measures:
  • Time to defervescence (24 hours of temperature <100 degrees F)
  • Return of WBC to normal (<10,500)
  • negative blood cultures
  • discharge

Estimated Enrollment: 160
Study Start Date: January 2006
Study Completion Date: January 2007
Primary Completion Date: January 2007 (Final data collection date for primary outcome measure)
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 64 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with MRSA in a blood culture processed as standard of care at the VAMC
  • Patients or next of kin willing to sign consent to be randomized by social security number to one of the treatments.

Exclusion Criteria:

  • none
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00304811

Locations
United States, Texas
Baylor College of Medicine
Houston, Texas, United States, 77030
Michael E. DeBakey Veterans Affairs Medical Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
VA Medical Center, Houston
Baylor College of Medicine
Investigators
Principal Investigator: Daniel M Musher, MD Baylor College of Medicine, Houston VA Medical Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00304811     History of Changes
Other Study ID Numbers: H-17556
Study First Received: March 16, 2006
Last Updated: September 25, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by VA Medical Center, Houston:
MRSA
Methicillin Resistant Staphylococcus aureus

Additional relevant MeSH terms:
Staphylococcal Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Gentamicins
Methicillin
Rifampin
Vancomycin
Anti-Bacterial Agents
Anti-Infective Agents
 Therapeutic Uses
Pharmacologic Actions
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antibiotics, Antitubercular
Antitubercular Agents
Leprostatic Agents
Nucleic Acid Synthesis Inhibitors

ClinicalTrials.gov processed this record on May 21, 2013